AVXL - アナベックス・ライフ・サイエンシズ （Anavex Life Sciences Corp.） アナベックス・ライフ・サイエンシズAVXLのチャート
AVXLの企業情報
| symbol | AVXL |
|---|---|
| 会社名 | Anavex Life Sciences Corp （アナベックス・ライフ・サイエンシズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Commercial Physical_Biological Resarch |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 アナヴェックス･ライフ・サイエンス(Anavex Life Sciences Corp.)は臨床段階のバイオ医薬品会社である。同社は神経変性疾患および神経発達疾患の治療用の差別化された治療薬の開発に従事する。その治療薬はアルツハイマー病（AD）、他の中枢神経系（CNS）疾患、疼痛および各種類の癌を治療するための薬物候補を含む。その研究開発パイプラインには、前臨床試験の各段階における臨床薬候補と多様な化合物が含まれる。製品パイプラインには、ANAVEX 2-73、ANAVEX 3-71、ANAVEX 1-41、ANAVEX 1037およびANAVEX 1066が含まれる。SIGMACEPTORディスカバリープラットフォームは、シグマ受容体の理解に基づいて、作用機序を有する小分子薬物候補を産生する。ANAVEX 1-41はシグマ-1アゴニストである。ANAVEX 1066は混合シグマ-1 /シグマ-2リガンドである。同社は事業から収入を得ていない。 アナベックス・ライフ・サイエンシズは米国の臨床段階のバイオ医薬品会社。アルツハイマ―病、中枢神経系疾患、前立腺がん、膵臓がんなどに焦点を当て、新しい候補薬の研究・開発を行う。シグマ受容体の働きに基づいて開発された、同社の「シグマセプタ―・ディスカバリ―・プラットフォ―ム」は、独特な方法により小分子候補薬を生産する。本社はニューヨーク。 Anavex Life Sciences Corp. is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system (CNS) diseases, pain and various types of cancer. Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), recently completed a successful Phase 2a clinical trial for Alzheimer's disease. ANAVEX®2-73 (blarcamesine) is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 (blarcamesine) also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 (blarcamesine) for the treatment of Parkinson's disease. ANAVEX®3-71, which targets sigma-1 and muscarinic receptors, is a promising preclinical drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. |
| 本社所在地 | 51 West 52nd Street 7th Floor New York NY 10019 USA |
| 代表者氏名 | Christopher U. Missling クリストファー・ミッシング |
| 代表者役職名 | President Chief Executive Officer Secretary Director |
| 電話番号 | +1 800-689-3939 |
| 設立年月日 | 37987 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 10人 |
| url | www.anavex.com |
| nasdaq_url | https://www.nasdaq.com/symbol/avxl |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -18.64204 |
| 終値（lastsale） | 2.48 |
| 時価総額（marketcap） | 112669636.4 |
| 時価総額 | 時価総額（百万ドル） 117.66710 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 91.83951 |
| 当期純利益 | 当期純利益（百万ドル） -16.81492 |
| 決算概要 | 決算概要 BRIEF: For the nine months ended 30 June 2018 Anavex Life Sciences Corp revenues was not reported. Net loss increased 40% to $11.7M. Higher net loss reflects Research and development - Balancing val increase of 88% to $6.9M (expense) General and administrative - Balancing increase of 68% to $2.5M (expense) Stock-based Compensation in SGA increase of 95% to $2M (expense). |
AVXLのテクニカル分析
AVXLのニュース
Analysts Predict Anavex Life Sciences Corp. (NASDAQ:AVXL) To Reach $42.00 In 12 Months 2022/10/15 18:00:00 Marketing Sentinel
In last trading session, Anavex Life Sciences Corp. (NASDAQ:AVXL) saw 0.66 million shares changing hands with its beta currently measuring 0.75. Company’s recent per share price level of $10.60 trading at -$0.37 or -3.37% at ring of the bell on the day assigns it a market valuation of $867.08M. That closing price of AVXL’s stock … Analysts Predict Anavex Life Sciences Corp. (NASDAQ:AVXL) To Reach $42.00 In 12 Months Read More »
Depression: Pharmaceutical and Therapeutics Latest Pipeline Guide 2022/10/13 18:30:00 SBWire
Pune, Maharashtra -- ( SBWIRE ) -- 10/13/2022 -- HTF Market Intelligence released a new research report of 668 pages on title ''Depression - Pipeline Review, H2 2022'' with detailed analysis, forecast and strategies. The market Study is segmented by key a region that is accelerating the marketization. The study is a perfect mix of qualitative and quantitative Market data collected and validated majorly through primary data and secondary sources. This section also provides the scope of different segments and applications that can potentially influence the market in the future. The detailed information is based on current trends and historic milestones. Download Sample Report PDF >>> https://www.htfmarketreport.com/sample-report/1014876-depression-pipeline-review-4 Depression - Pipeline Review, H2 2022 Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches.
Anavex Life Sciences Corp. (NASDAQ: AVXL) Fell -143.38% From Highs, What Does The Future Hold? 2022/09/30 15:00:00 Marketing Sentinel
Anavex Life Sciences Corp. (NASDAQ:AVXL)’s traded shares stood at 1.08 million during the last session, with the company’s beta value hitting 0.83. At the close of trading, the stock’s price was $9.75, to imply a decrease of -6.70% or -$0.7 in intraday trading. The AVXL share’s 52-week high remains $23.73, putting it -143.38% down since … Anavex Life Sciences Corp. (NASDAQ: AVXL) Fell -143.38% From Highs, What Does The Future Hold? Read More »
Anavex Life Sciences Announces Issuance of U.S. Patent Covering ANAVEX®2-73 (blarcamesine) for Neurodevelopmental Disorders Therapy 2022/09/21 11:00:00 GlobeNewswire
Issuance of Anavex’s Newest U.S. Patent Will Expand Anavex’s Intellectual Property Portfolio Surrounding ANAVEX®2-73 Issuance of Anavex’s Newest U.S. Patent Will Expand Anavex’s Intellectual Property Portfolio Surrounding ANAVEX®2-73
Anavex Life Sciences Announces Issuance of U.S. Patent Covering ANAVEX2-73 (blarcamesine) for Neurodevelopmental Disorders Therapy 2022/09/21 11:00:00 Wallstreet:Online
Issuance of Anavex’s Newest U.S. Patent Will Expand Anavex’s Intellectual Property Portfolio Surrounding ANAVEX2-73 NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders
Anavex Life Sciences Corp. (NASDAQ: AVXL) Is Expected To Rise To 42.00 USD! 2022/09/10 12:00:00 Stocks Register
Anavex Life Sciences Corp. (NASDAQ:AVXL) price on Friday, September 09, rose 3.31% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $10.30. A look at the stock’s price movement, the close in the last trading session was $9.97, moving within a range at $9.935 and $10.39. The beta … Anavex Life Sciences Corp. (NASDAQ: AVXL) Is Expected To Rise To 42.00 USD! Read More »
Anavex Life Sciences Corp. (NASDAQ:AVXL) 22.67% Above Its 52-Week Low, But Can It Keep Rising? 2022/09/03 17:00:00 Marketing Sentinel
In last trading session, Anavex Life Sciences Corp. (NASDAQ:AVXL) saw 0.53 million shares changing hands with its beta currently measuring 0.79. Company’s recent per share price level of $9.22 trading at -$0.43 or -4.46% at ring of the bell on the day assigns it a market valuation of $783.98M. That closing price of AVXL’s stock … Anavex Life Sciences Corp. (NASDAQ:AVXL) 22.67% Above Its 52-Week Low, But Can It Keep Rising? Read More »
Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Relevance of SIGMAR1 Activation to Compensate for Early Alzheimer''s Disease 2022/08/23 11:00:00 Wallstreet:Online
Mechanism of Action of ANAVEX2-73 (blarcamesine) and ANAVEX3-71 (AF710B) is the activation of SIGMAR1 Endogenous increase in SIGMAR1 activation as a compensatory mechanism against early Alzheimer''s disease Top line results of randomized, placebo-controlled Phase 2b/3 study ANAVEX2-73-AD-004 for the treatment of early Alzheimer''s disease are expected in the fall of 2022 NEW YORK, Aug. 23,
Anavex Life Sciences (AVXL) Investor Presentation - Slideshow 2022/08/12 15:37:35 Seeking Alpha
The following slide deck was published by Anavex Life Sciences Corp.
Anavex And The Debunking Of The Amyloid Hypothesis (NASDAQ:AVXL) 2022/08/11 14:17:06 Seeking Alpha
Recent research is claiming pivotal study data was falsified in order to bolster the amyloid hypothesis. This should have a positive impact on Alzheimer''s programs based on other mechanisms.
Biofrontera, Synaptogenix top healthcare gainers; while Sio Gene, Anavex among losers 2022/02/01 15:02:51 Seeking Alpha
Biofrontera (BFRI) +14%. Synaptogenix (SNPX) +11%. Sio Gene Therapies (SIOX) -19%. Anavex Life Sciences (AVXL) -16%.
Anavex says late-stage trial for Rett syndrome met main goals 2022/02/01 12:37:27 Seeking Alpha
Announcing topline data from its AVATAR trial for ANAVEX2-73 (blarcamesine), Anavex Life Sciences (AVXL) said that the Phase 3 study met primary and secondary efficacy endpoints in
ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial met Primary and Secondary Efficacy Endpoints for the Treatment of Adult Patients with Rett Syndrome 2022/02/01 12:00:00 Benzinga
Primary and all secondary efficacy and safety endpoints met, with consistent improvements in RSBQ AUC (p = 0.037), ADAMS (p = 0.010) and CGI-I (p = 0.037) response Efficacy endpoints demonstrated statistically significant and clinically meaningful reductions in Rett syndrome symptoms with related changes in potential biomarkers (GABA and L-AAA) of disease pathology Key milestone met to advance regulatory approval pathway for adult patients with Rett syndrome Company to host a webcast today at 8:30 a.m. ET NEW YORK, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ: AVXL ), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer''s disease, Parkinson''s disease, Rett syndrome and other central nervous system (CNS) disorders, today reported positive top-line results from the Phase 3 randomized, double-blind, placebo-controlled AVATAR trial of ANAVEX ® 2-73 ( blarcamesine ) in adult female patients with Rett syndrome and demonstrated a statistically significant improvement over placebo for the primary efficacy endpoint as well as for all the secondary efficacy endpoints.
Integral Ad Science leads postmarket gainers; Apyx Medical top loser 2022/01/21 22:49:54 Seeking Alpha
Gainers: Integral Ad Science (IAS) +14%, Anavex Life Sciences (AVXL) +8%, Algoma Steel (ASTL) +5%, EMCORE (EMKR) +4%, CymaBay Therapeutics (CBAY) +4%.Losers: Apyx Medical (APYX)
Parkinson''s Disease Pipeline Offers Promising New Options for Treatment | DelveInsight 2022/01/18 01:00:00 Benzinga
Los Angeles, USA, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Parkinson''s Disease Pipeline Offers Promising New Options for Treatment | DelveInsight DelveInsight''s "Parkinson''s Disease Pipeline Insight" report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in the Parkinson''s Disease pipeline landscapes. The report comprises Parkinson''s Disease pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Parkinson''s Disease therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Parkinson''s Disease pipeline products. Some of the key takeaways from the Parkinson''s Disease Pipeline Report Major Parkinson''s Disease companies such as Cerevel Therapeutics, Abbvie, Pharma Two B, Roche, Kissei Pharmaceutical, Peptron, Inc., Lundbeck A/S, AstraZeneca, Nobilis Therapeutics, Treefrog Therapeutics, Cantabio Pharmaceuticals, Anavex Life Sciences, Ipsen, Prevail Therapeutics, AFFiRiS, Sio Gene Therapies, UCB Pharma, Brain Neurotherapy Bio, Inc., Neuraly, Inc., NeuroDerm, BlueRock Therapeutics, Sun Pharma Advanced Research Company, Xoc Pharmaceuticals, Hong Kong WD Pharmaceutical, 1ST Biotherapeutics, Inc., Biogen, Denali Therapeutics, Inhibikase Therapeutics,Cerevance, Aspen Neuroscience,Prilenia Therapeutics,Cortexyme Inc.,Gain Therapeutics, Clexio Biosciences, Orpheris, Inc., Alkahest, Inc., and others are developing potential drug candidates to improve the Parkinson''s Disease treatment scenario.